Database guide last
updated May 21, 2024

Copyright 2024,
Wolters Kluwer Health

The Transplant Library is the bibliographic database of the Centre for Evidence in Transplantation (CET) which is based at the Nuffield Department of Surgical Sciences, University of Oxford, UK.

The Transplant Library contains records of:

• randomised controlled trials (RCTs) in solid organ transplantation, from 1970 to present, including conference proceedings. Records of ongoing randomised controlled trials come from a number of trial registries.
• Systematic reviews and meta-analyses of good quality from 2008 onwards.
• Clinical practice guidelines from 2005
• Studies of COVID-19 in solid organ transplantation

The CET uses a customized literature search in Medline (Ovid) and Cochrane Central bibliographic databases (with permission) to retrieve relevant transplantation records. The listing of RCTs is updated every two weeks. After the records are downloaded from these commercially-available databases, additional information is manually added to each record, based on certain indexing criteria, by CET personnel. Quality rating of methodology is available for most RCTs published since 2004 using both the Jadad scale (0-5) and the items concealed allocation and statistical analysis.

The Transplant Library includes a selection of systematic reviews (SR) and meta-analyses published from 2008 to the present. Systematic reviews and meta-analyses must meet a number of criteria before inclusion in the Transplant Library. The listing of reviews is updated every month. To be included in the Transplant Library a review should at least satisfy three of the following criteria:

• The review addresses a clearly focused question and the describes the inclusion and exclusion criteria of the review (mandatory requirement)
• The literature search is sufficiently rigorous to identify all relevant studies (mandatory requirement)
• The study quality of included studies is assessed and reported
• Sufficient details of the individual included studies are presented
• An adequate description of the methodology used to analyse the data is included and the methods used are appropriate to the question

For more information or to receive training on the Transplant Library, please send your queries to [email protected]

The limit of databases that you can select for a multifile search session is based upon database segments rather than actual databases. The Ovid multifile segment limit is set at 120 to avoid impacting your search sessions. This database includes 1 segment.

This database is updated online bi-weekly.

If you experience difficulty in downloading references into EndNote this may be due to the correct import filter not being installed. Import filters can be downloaded from the EndNote (www.endnote.com) website within the Support and Services section.

The details of the required filter are:

• Database - Transplant Library
• Information Provider - Ovid SP

The import filter will need to be downloaded and saved into the filters folder of your EndNote package. This can be found by opening Program files, double clicking on EndNote and then opening the Filters folder. This may need to be performed by an administrator.

Quotation marks can be used to retrieve records that contain literal strings, when the string includes special characters, such as a forward slash (/).

Quotation marks can also be used to retrieve records that contain numbers that may otherwise be confused for earlier searches. In the example, a search for 3.vo would limit the string from your third search in your search history to the Volume (VO) field. By including the number in quotation marks, the search will retrieve documents with a 3 in the volume number.

The Ovid search engine applies so called "run-time stopword processing". This means the search engine on the fly ignores the stopwords: and, as, by, for, from, in, is, of, on, that, the, this, to, was, were & with.

Therefore a search: at risk for diabetes.ti will also find: at risk of diabetes. The distance of one word in between is kept, but the stopword "for" is ignored.

A limit to Full Text restricts retrieval to records that have links to full text. Both Ovid full text and external full text are included in this limit.

A limit to Ovid Full Text Available restricts retrieval to those citations where an Ovid full text link is available. When viewing a citation with full text available use the LINK button to display the full text.

A limit to Various Organ Transplant restricts retrieval to records where:

• the organ transplanted is not specified, or
• studies include multiple types of organ transplants.

The following Search Tools are available for this database. For specific information on using these tools, refer to the Ovid Online Help linked below.

• Tree
• Permuted Index
• Scope Notes
• Explode
• Subheadings

Click on this link to see other Advanced Search Techniques

Unique Identifier
   9736
Authors
   Drechsler C, Pihlstrom H, Meinitzer A, Pilz S, Tomaschitz A, Abedini S, Fellstrom B, Jardine AG, 
   Wanner C, Marz W, Holdaas H.
Author Email
   [email protected].
Title
   Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment 
   of Lescol in Renal Transplantation Study.
Institution
   1 Division of Nephrology, Department of Medicine, University Hospital Wurzburg, Wurzburg, 
   Germany. 2 Comprehensive Heart Failure Centre, University Hospital of Wurzburg, Wurzburg, 
   Germany. 3 Department of Organ Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, 
   Norway. 4 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of 
   Graz, Graz, Austria. 5 Department of Epidemiology and Biostatistics, EMGO Institute for Health 
   and Care, Research, VU University Medical Centre, Amsterdam, the Netherlands. 6 Division of 
   Endocrinology and Metabolism, Department of Internal Medicine, Medical, University of Graz, 
   Graz, Austria. 7 Department of Cardiology, Medical University of Graz, Graz, Austria. 8 Specialist 
   Clinic for Rehabilitation Bad Aussee, Bad Aussee, Austria. 9 Division of Nephrology, Department of 
   Medicine, Sykehuset i Vestfold, Tonsberg, Norway. 10 Division of Nephrology, Department of 
   Internal Medicine, Uppsala University Hospital, Uppsala, Sweden. 11 Institute of Cardiovascular 
   and Medical Sciences, University of Glasgow, Glasgow, UK. 12 Department of Medicine V 
   (Nephrology, Hypertensiology, Endocrinology, Rheumatologie) Mannheim Medical Faculty 
   Mannheim, University of Heidelberg, Mannheim, Germany. 13 Clinical Institute of Medical and 
   Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. 14 Synlab Academy, 
   Synlab Services, Mannheim, Germany.
Source
   Transplantation. 99(7): 1470-6, 2015.
Publication Type
   Randomised Controlled Trial
Organ Type
   Kidney transplant
Language
   English
Funding Information
   Industry funding
Allocation Concealment
   Yes
Statistical Analysis
   Intention to treat
Jadad Score (0-5)
   5 (Score based on previous publication - Holdaas, H. et al. Nephrology Dialysis Transplantation 
   20(5): 974-980. 2005)
Abstract
   BACKGROUND: Despite improvements in kidney transplantation, complications, including 
   cardiovascular morbidity and graft loss, contribute to reduced graft and patient survival. The 
   amino acid homoarginine exerts a variety of beneficial effects that may be relevant for 
   cardiovascular and graft outcomes, which is investigated in the present study. METHODS: 
   Homoarginine was measured in 829 renal transplant recipients participating in the placebo group 
   of the Assessment of Lescol in Renal Transplantation study. Mean follow-up was 6.7 years. By Cox 
   regression analyses, we determined hazard ratios (HRs) to reach prespecified, adjudicated 
   endpoints according to baseline homoarginine levels: major adverse cardiovascular events (n = 
   103), cerebrovascular events (n = 53), graft failure or doubling of serum creatinine (n = 140), 
   noncardiovascular mortality (n = 51), and all-cause mortality (n = 107). RESULTS: Patients mean 
   age was 50 +/- 11 years, homoarginine concentration was 1.96 +/- 0.76 mumol/L, and 65% were 
   men. Patients in the lowest homoarginine quartile (<1.40 mumol/L) had an adjusted 2.6-fold 
   higher risk of cerebrovascular events compared to those in the highest quartile (>2.34 mumol/L) 
   (HR, 2.56; 95% confidence interval [95% CI], 1.13-5.82). Similarly, the renal endpoint occurred at 
   a significantly increased rate in the lowest homoarginine quartile (HR, 2.34; 95% CI, 1.36-4.02). 
   For noncardiovascular and all-cause mortality, there was also increased risk associated with the 
   lowest levels of homoarginine, with HRs of 4.34 (95% CI, 1.63-10.69) and 2.50 (95% CI, 
   1.38-4.55), respectively. CONCLUSIONS: Low homoarginine is strongly associated with 
   cerebrovascular events, graft loss and progression of kidney failure and mortality in renal 
   transplant recipients. Whether interventions with homoarginine supplementation improve clinical 
   outcomes requires further evaluation.
Subject Headings
   Kidney Transplantation
   Adult
   Biomarkers / bl [Blood]
   Cardiovascular Diseases / bl [Blood]
   Cardiovascular Diseases / di [Diagnosis]
   *Cardiovascular Diseases / et [Etiology]
   Cardiovascular Diseases / mo [Mortality]
   Chi-Square Distribution
   Creatinine / bl [Blood]
   Disease Progression
   Europe
   *Fatty Acids, Monounsaturated / tu [Therapeutic Use]
   Female
   Graft Rejection / bl [Blood]
   Graft Rejection / di [Diagnosis]
   *Graft Rejection / et [Etiology]
   Graft Rejection / mo [Mortality]
   Graft Survival
   *Homoarginine / bl [Blood]
   Humans
   *Hydroxymethylglutaryl-CoA Reductase Inhibitors / tu [Therapeutic Use]
   *Indoles / tu [Therapeutic Use]
   *Kidney Transplantation / ae [Adverse Effects]
   Kidney Transplantation / mo [Mortality]
   Male
   Middle Aged
   Multivariate Analysis
   North America
   Proportional Hazards Models
   Prospective Studies
   Renal Insufficiency / bl [Blood]
   Renal Insufficiency / di [Diagnosis]
   *Renal Insufficiency / et [Etiology]
   Renal Insufficiency / mo [Mortality]
   Risk Factors
   Time Factors
   Treatment Outcome
ISSN
   0041-1337
ISSN Electronic
   1534-6080  
Update Code
   20170627

              

Unique Identifier
   9964
Year
   2014   
Principal Investigator
   Wiwat Chancharoenthana, MD.,MSc. Chulalongkorn University, Thailand
Title
   Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney 
   Transplantation.
Trial Registration	
   Clinicaltrials.gov - NCT02294097
Start Date
   November 2014
Estimated Completion
   December 2016
Study Status
   Recruiting
Publication Type
   Trial Registry Record
Organ Type
   Kidney transplant
Funding Information
   Non-industry funding
Subject Headings
   Kidney Transplantation
URL
   http://ClinicalTrials.gov/show/N...
Update Code
   20170627
                  

Reshma Rana Magar
Systematic Reviewer
Peter Morris Centre for Evidence in Transplantation
Nuffield Department of Surgical Sciences
University of Oxford
OX3 9DU
T: 020 7869 6626
E: [email protected]
M: www.rcseng.ac.uk